Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating RO7443904 in combination with glofitamab for relapsed/refractory B-cell non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• RO7443904

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: TERMINATED